Cargando…
A short review on antibody therapy for COVID-19
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychl...
Autores principales: | Venkat Kumar, G., Jeyanthi, V., Ramakrishnan, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167584/ https://www.ncbi.nlm.nih.gov/pubmed/32313660 http://dx.doi.org/10.1016/j.nmni.2020.100682 |
Ejemplares similares
-
Antibody glycosylation in COVID-19
por: Pongracz, Tamas, et al.
Publicado: (2022) -
Plant-based vaccines and antibodies to combat COVID-19: current status and prospects
por: Dhama, Kuldeep, et al.
Publicado: (2020) -
The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization
por: Kellogg, Caitlyn, et al.
Publicado: (2020) -
Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections
por: Parray, Hilal Ahmad, et al.
Publicado: (2021) -
The variability of responses to growth hormone therapy in children with short stature
por: Savage, Martin O., et al.
Publicado: (2012)